Table 3 Selected characteristics of studies investigating commercial tests for the diagnosis of extrapulmonary tuberculosis.

Reference	Data collection	Verification	Reference standard	Disease site	Country	Comparison group	Name of test*	No. of participants‡	Sensitivity (95% CI)	Specificity (95% CI)
Banerjee (2003, b)42	Retrospective	NR	Histology	Lymph node	India	Healthy	SEVA TB	30/32	0.77 (0.58 to 0.90)	0.88 (0.71 to 0.97)
McConkey (2002)48†	Prospective	Complete	Culture	Meninges	Egypt	Mixed disease	AMRAD ICT	56/74	0.48 (0.35 to 0.62)	0.82 (0.72 to 0.90)
Nsanze (1997, a)49	Prospective	Differential	Culture and/ or smear	NR	UAE	Mixed disease and healthy	Pathozyme Myco	35/35	0.51 (0.34 to 0.69)	1.00 (0.90 to 1.00)
Nsanze (1997, b)49	Prospective	Differential	Culture and/ or smear	NR	UAE	Mixed disease and healthy	Pathozyme TB Complex Plus	35/35	0.11 (0.03 to 0.27)	1.00 (0.90 to 1.00)

NR, not reported.

*All commercial tests detected immunoglobulin G antibody.

†Blinded study.

‡Number of participants with tuberculosis/without tuberculosis.